Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Policy / Pricing

Regeneron cuts White House pricing deal, offers new gene therapy for free

 April 24, 2026

Pharmaceutical Technology

This White House deal will see Regeneron offer all its new medicines at “MFN prices”, while providing Otarmeni for free to eligible patients.

Policy / PricingGene Therapy PlatformRead full story

Post navigation

Cumberland to sell drug portfolio to Apotex for $100m →
← Cardiometabolic trials: Using expertise to turn complexity into robust results

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com